VDPHL01: The First Non-Hormonal Oral Hair Loss Pill Nears FDA

There is a strange gap at the centre of hair loss medicine. The oral minoxidil dermatologists prescribe more every year was never designed for hair. It is a blood-pressure pill borrowed off-label, at doses no regulator approved for the scalp. It works, but it is improvised.

VDPHL01 is what happens when someone finally engineers an oral minoxidil for hair on purpose. In April 2026 it did something no oral hair loss pill has managed in nearly three decades: it posted positive Phase 3 data. If it clears the finish line, it would be the first FDA-approved oral treatment for pattern hair loss in a generation.

The quick answer

What is VDPHL01? An extended-release oral minoxidil tablet, purpose-built for hair loss by Veradermics, using a gel-matrix formulation to release minoxidil slowly and steadily, unlike the off-label blood-pressure pills used today.

Does it work? In a 519-man Phase 2/3 trial, it grew roughly four times as many new hairs as placebo (about 30 to 33 hairs/cm² versus 7.3), meeting both primary goals with high statistical significance.

Is it safer than regular oral minoxidil? That is the design goal. By avoiding the blood-concentration spikes of standard oral minoxidil, it aims to reduce cardiac risk; the trial reported no cardiac adverse events.

When will it be available? Confirmatory Phase 3 results are due late 2026, with FDA submission expected around early 2027 and possible launch late 2027 to 2028.

The Problem VDPHL01 Was Built to Solve

To understand why this matters, understand the awkward truth about the oral minoxidil boom.

Standard oral minoxidil was made for blood pressure. When you swallow it, blood levels spike, then fall, and that spike is what can strain the heart, which is why the off-label use, however popular, still makes cardiologists watchful. The drug growing hair for millions was built for a different organ.

VDPHL01 attacks this at the formulation level. Its extended-release gel matrix releases minoxidil slowly and steadily rather than all at once, keeping the drug above the hair-growth threshold as long as possible while avoiding the peaks linked to cardiac effects. More of what grows hair, less of what stresses the heart, from the same molecule people already trust, the difference between borrowing a tool and building one.

What the Phase 3 Data Showed

The headline results come from Study '302', and they are strong.

This was a randomised, double-blind, placebo-controlled Phase 2/3 trial in 519 men with mild-to-moderate pattern hair loss, testing VDPHL01 at 8.5 mg once daily, 8.5 mg twice daily, or placebo, assessed at six months. It met both co-primary endpoints with high statistical significance.

Measured by new non-vellus hair count, the once-daily group gained an average of 30.3 hairs per square centimetre and the twice-daily group 33.0, versus just 7.3 on placebo, four times the placebo response (p less than 0.0001 for both). Patients noticed too: on the self-rating scale, 79.3% of once-daily and 86.0% of twice-daily patients reported improvement against 35.6% on placebo, and nearly two-thirds of the twice-daily group rated themselves "improved" or "much improved" versus 13.4%. Growth you measure under a microscope is one thing; growth people see in the mirror is what changes lives.

The Safety Result That Matters Most

For a drug whose premise is "safer oral minoxidil," the safety data is the real test, and it delivered.

The trial reported no treatment-related serious adverse events and, crucially, no cardiac adverse events of special interest. More telling still, VDPHL01 showed lower discontinuation than placebo, people were likelier to quit the sugar pill than the drug, a strong tolerability signal.

The quietly impressive number in the trial is the dropout rate: people stuck with VDPHL01 better than with placebo. In a field where treatments fail mostly because people abandon them, a drug that is easy to keep taking is one that works in real life.

The no-cardiac-events finding is the one to watch as larger data arrives. A single trial does not settle safety permanently, but as a first pivotal readout, it is exactly what the design predicted.

VDPHL01 vs the Oral Minoxidil People Take Now

This comparison matters most, as oral minoxidil is already everywhere.

The oral minoxidil prescribed today is an immediate-release blood-pressure tablet, split to tiny doses off-label. It works, but was never studied in a long-term, purpose-built hair loss trial, and its blood-level spikes drive its cardiac caution. VDPHL01 is the same drug re-engineered: extended-release, dose-optimised for hair, tested in a proper registration programme. If approved, it moves oral minoxidil from "effective improvisation" to "approved treatment."

But "better formulation" is not "available." The off-label version exists now; VDPHL01 does not, which brings us to the timeline.

When Will VDPHL01 Be Available?

Here is the honest schedule.

The Study '302' data is one pivotal piece, not the finish line. A confirmatory Phase 3 male trial, Study '304' (536 men), has completed enrolment with topline results due in the second half of 2026, and a female trial, Study '306', is still recruiting. Only once the confirmatory male data reads out can the company file with the FDA, expected around early 2027, pointing to a possible US launch in late 2027 to 2028 if the trial holds. For Pakistan, add the usual multi-year lag after any US or European approval. VDPHL01 is not available anywhere today, only the older off-label oral minoxidil exists now, and that requires a doctor.

What This Means If You Are Losing Hair Now

VDPHL01 is one of the most encouraging near-term developments in hair loss, precisely because it is not exotic, a better version of something already proven, moving through a real approval process. But "near-term" still means years, and years matter, because untreated hair loss keeps progressing while you wait. The follicles you protect now are the ones any future treatment must work with.

For active pattern hair loss today, the proven approach remains topical minoxidil plus finasteride, delivered together in the hair fall solution range at verified concentrations. If the daily routine is your obstacle, the honest answer is a doctor conversation about existing oral minoxidil, not a wait for VDPHL01, and the finasteride side effects guide covers the DHT half. The full hair care range is built for the long game: keep your hair now, so you are ready when the engineered pill arrives.

Frequently Asked Questions

What is VDPHL01?

An investigational extended-release oral minoxidil tablet developed by Veradermics specifically for pattern hair loss. Unlike the off-label blood-pressure minoxidil used today, it uses a gel-matrix formulation to release the drug slowly, aiming for better hair growth with less cardiac risk. It is in Phase 3.

Is VDPHL01 better than regular oral minoxidil?

It is designed to be. By releasing minoxidil steadily instead of in a spike, it aims to grow more hair while avoiding the blood-level peaks linked to cardiac effects, and its Phase 3 trial showed roughly four times the hair growth of placebo with no cardiac adverse events. But it is not yet available, while off-label oral minoxidil is.

Kya VDPHL01 Pakistan mein milta hai?

Nahi. VDPHL01 abhi kisi bhi mulk mein available nahi hai, yeh Phase 3 trials mein hai. FDA submission 2027 ke qareeb expected hai, aur Pakistan tak pahunchne mein kaafi saal lagenge. Filhaal proven treatment, jaise topical minoxidil aur finasteride, hi behtareen option hai.

VDPHL01 aur aam oral minoxidil mein kya farq hai?

Aam oral minoxidil blood pressure ki dawa hai jo off-label istemal hoti hai, aur uska blood level tezi se barhta hai jo dil par asar daal sakta hai. VDPHL01 wahi minoxidil hai lekin extended-release formulation ke sath, jo dawa dheere dheere release karta hai, taake baal zyada barhein aur dil par asar kam ho.

The Bottom Line

VDPHL01 is not a new molecule or an exotic mechanism. It is something arguably more useful: a smart redesign of a drug that already works, built to fix its biggest weakness. Its Phase 3 data, four times the hair growth of placebo and no cardiac events, is exactly what the field has been waiting for, and if the confirmatory trial holds, it could become the first FDA-approved oral hair loss pill in nearly 30 years. But it is still a 2027-and-beyond prospect, further for Pakistan, and unavailable today at any price. Protect the hair you have with proven treatment while the engineered pill works through trials, so there is something for the better tool to build on when it arrives.

Hair Fall Solution Collection | Full Hair Care Range | Minoxidil Shedding Phase Guide